{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-23-000047","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.323471+00:00","generated_at":"2026-06-18T18:28:00.292048+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zentalis FY2022 cash $437M, R&D $172.7M; azenosertib RP2D on track for 1H 2023","bullets":["Cash, cash equivalents and marketable securities of $437.4M as of Dec 31, 2022; projected cash runway into Q2 2025.","R&D expenses $172.7M for FY2022 (vs $175.6M in 2021); G&A expenses $54.5M (vs $40.9M).","On track to declare azenosertib monotherapy RP2D in 1H 2023; Cyclin E1 enrichment strategy in ovarian cancer.","Appointed Iris Roth, PhD as Chief Operating Officer in February 2023.","Initiated enrollment in Phase 1/2 azenosertib + BEACON regimen (Pfizer) in BRAF V600E mCRC."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-23-000047","json":"https://secwatch.observer/filing/0001725160-23-000047.json","markdown":"https://secwatch.observer/filing/0001725160-23-000047.md","text":"https://secwatch.observer/filing/0001725160-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000047/0001725160-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000047/zntl-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:28:00.292048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ddf2be9cdf7280ffed8789d7acc8e0fbe82c04b1","claim":"Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000047/0001725160-23-000047-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}